The estimated Net Worth of Johnson Yiu Nam Lau is at least $5.19 Million dollars as of 19 August 2022. Johnson Lau owns over 20,000 units of Athenex Inc stock worth over $710,634 and over the last 7 years he sold ATNX stock worth over $0. In addition, he makes $4,483,840 as Chief Executive Officer and Chairman of the Board at Athenex Inc.
Johnson has made over 66 trades of the Athenex Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 20,000 units of ATNX stock worth $9,000 on 19 August 2022.
The largest trade he's ever made was buying 40,000 units of Athenex Inc stock on 14 November 2018 worth over $418,800. On average, Johnson trades about 5,684 units every 18 days since 2017. As of 19 August 2022 he still owns at least 3,553,172 units of Athenex Inc stock.
You can see the complete history of Johnson Lau stock trades at the bottom of the page.
Dr. Johnson Y.N. Lau M.D. serves as Chief Executive Officer and Chairman of the Board of the Company. Dr. Lau has served as our Chief Executive Officer since 2011 and as Chairman of our Board since our inception in 2003. Dr. Lau has had extensive leadership experience in both scientific and business management. He previously served as Chairman and Chief Executive Officer of Ribapharm Inc. (“Ribapharm”), a company that engages in the development, acquisition, and commercialization of products for the treatment of diseases principally in the antiviral and anticancer areas, and oversaw the company’s initial public offering in 2002. Ribapharm was acquired by Valeant Pharmaceuticals International (now known as Bausch Health) in 2003. Prior to Ribapharm, he served as Senior Vice President and Head of Research and Development for the pharmaceutical company, ICN Pharmaceuticals Inc. (“ICN”). Prior to joining ICN, Dr. Lau served as the Senior Director of Antiviral Therapy Research at the pharmaceutical company, Schering-Plough Corporation. Dr. Lau has contributed more than 200 scientific publications, editorials/reviews and chapters in peer reviewed scientific journals and has edited two books. He was a Director of the Board of Chelsea Therapeutics International, Ltd., a pharmaceutical company, serving as the Chair of the Audit and Risk Management Committee as well as the Corporate Governance Committee. He previously served on the board of Porton Fine Chemicals Ltd., a pharmaceutical company now known as Porton Pharma Solutions Ltd. (“Porton”). Dr. Lau has received a notice from the China Securities Regulatory Commission (“CSRC”) in connection with his board service proposing that he pay an administrative fine of RMB 100,000 (approximately $14,150) in connection with certain accounting and compliance infractions at Porton that occurred while he served as a director. Dr. Lau has submitted a letter to the CSRC to oppose the proposed fine. Dr. Lau also serves on the board of directors of private companies including Avalon Bi
As the Chief Executive Officer and Chairman of the Board of Athenex Inc, the total compensation of Johnson Lau at Athenex Inc is $4,483,840. There are no executives at Athenex Inc getting paid more.
Johnson Lau is 59, he's been the Chief Executive Officer and Chairman of the Board of Athenex Inc since 2011. There are 10 older and 6 younger executives at Athenex Inc. The oldest executive at Athenex Inc is John Vierling, 74, who is the Independent Director.
Johnson's mailing address filed with the SEC is C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO, NY, 14203.
Over the last 7 years, insiders at Athenex Inc have traded over $33,215,399 worth of Athenex Inc stock and bought 5,920,005 units worth $73,651,360 . The most active insiders traders include Advisors Llcperceptive Life..., Song Yi Zhang, and Song Yi Mandra Medical Ltd .... On average, Athenex Inc executives and independent directors trade stock every 12 days with the average trade being worth of $10,843. The most recent stock trade was executed by Joe Annoni on 22 February 2023, trading 625 units of ATNX stock currently worth $125.
athenex is a global specialty oncology pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies. the company is dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients. our business includes medical technology innovation centers and a unique manufacturing supply chain across both china and north america. through the connected innovation and manufacturing supply chain presence, we can identify, develop and deliver proprietary medical technology across continents and multiple regulatory environments.
Athenex Inc executives and other stock owners filed with the SEC include: